FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213961504> ?p ?o ?g. }

• W3213961504 endingPage "1740" @default.
• W3213961504 startingPage "1725" @default.
• W3213961504 abstract "Hepatocellular carcinoma (HCC) is characterized by dysregulation of the immune microenvironment and the development of chemoresistance. Specifically, expression of the programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis, an immune checkpoint, may lead to tumour immune escape, resulting in disease progression. The latest research shows that tumour immune escape may be caused by the upregulation of PD-L1 mediated by hypoxia-inducible factor-1 alpha (HIF-1α), and simultaneous inhibition of HIF-1α and PD-L1 has the potential to enhance the host's antitumour immunity. Moreover, inhibition of the PD-1/PD-L1 axis may mitigate tumour chemoresistance. Shuyu pills (SYPs) contain immunity-enhancing and antitumour components, making them a potential HCC treatment.To investigate the efficacy of SYPs for HCC treatment via simultaneous HIF-1α and PD-L1 inhibition and the mechanism involved.A subcutaneous xenograft tumour model was first established in BALB/c nude mice by the subcutaneous injection of 1 × 107 SMMC-7721 cells. Male mice (male, 5 weeks old; n = 24) were then randomly divided into the following four groups (n = 6): Control (0.9% normal saline), SYP (200 mg/kg), SYP + cisplatin (DDP) (200 mg/kg + 5 mg/kg DDP weekly via intraperitoneal injection), and DDP (5 mg/kg cisplatin weekly via intraperitoneal injection). The dose of saline or SYPs for the indicated mouse groups was 0.2 mL/d via intragastric administration. The tumour volumes and body weights of the mice were measured every 2 d. The mice were euthanized by cervical dislocation after 14 d of continuous treatment, and the xenograft tissues were excised and weighed. Western blot assays were used to measure the protein expression of HIF-1α, PD-1, PD-L1, CD4+ T cells, and CD8+ T cells in HCC tumours from mice. Quantitative reverse transcription polymerase chain reaction was used for real-time quantitative detection of PD-1, PD-L1, and HIF-1α mRNA expression. An immunofluorescence assay was conducted to examine the expression of CD4+ T cells and CD8+ T cells.Compared to mice in the control group, those in the SYP and SYP + DDP groups exhibited reduced tumour volumes and tumour weights. Moreover, the protein and mRNA expression levels of the oncogene HIF-1α and that of the negative immunomodulatory factors PD-1 and PD-L1 were decreased in both the SYP and SYP + DDP groups, with the decrease effects being more prominent in the SYP + DDP group than in the SYP group (HIF-1α protein: Control vs SYP, P = 0.0129; control vs SYP + DDP, P = 0.0004; control vs DDP, P = 0.0152, SYP + DDP vs DDP, P = 0.0448; HIF-1α mRNA: control vs SYP, P = 0.0009; control vs SYP + DDP, P < 0.0001; control vs DDP, P = 0.0003, SYP vs SYP + DDP, P = 0.0192. PD-1 protein: Control vs SYP, P = 0.0099; control vs SYP + DDP, P < 0.0001, SPY vs SYP + DDP, P = 0.0009; SYP + DDP vs DDP, P < 0.0001; PD-1 mRNA: control vs SYP, P = 0.0002; control vs SYP + DDP, P < 0.0001; control vs DDP, P = 0.0003, SPY vs SYP + DDP, P = 0.0003; SYP + DDP vs DDP, P = 0.0002. PD-L1 protein: control vs SYP, P < 0.0001; control vs SYP + DDP, P < 0.0001; control vs DDP, P < 0.0001, SPY vs SYP + DDP, P = 0.0040; SYP + DDP vs DDP, P = 0.0010; PD-L1 mRNA: Control vs SYP, P < 0.0001; control vs SYP + DDP, P < 0.0001; control vs DDP, P < 0.0001, SPY vs SYP + DDP, P < 0.0001; SYP + DDP vs DDP, P = 0.0014). Additionally, the quantitative and protein expression levels of CD4+ T cells and CD8+ T cells were simultaneously upregulated in the SYP + DDP group, whereas only the expression of CD4+ T cells was upregulated in the SYP group. (CD4+ T cell quantitative: Control vs SYP + DDP, P < 0.0001, SYP vs SYP + DDP, P = 0.0005; SYP + DDP vs DDP, P = 0.0002. CD4+ T cell protein: Control vs SYP, P = 0.0033; Control vs SYP + DDP, P < 0.0001; Control vs DDP, P = 0.0021, SYP vs SYP + DDP, P = 0.0004; SYP + DDP vs DDP, P = 0.0006. Quantitative CD8+ T cells: Control vs SYP + DDP, P = 0.0013; SYP vs SYP + DDP, P = 0.0347; SYP + DDP vs DDP, P = 0.0043. CD8+ T cell protein: Control vs SYP + DDP, P < 0.0001; SYP vs SYP + DDP, P < 0.0001; SYP + DDP vs DDP, P < 0.0001). Finally, expression of HIF-1α was positively correlated with that of PD-1/PD-L1 and negatively correlated with the expression of CD4+ T cells and CD8+ T cells.SYPs inhibit immune escape and enhance chemosensitization in HCC via simultaneous inhibition of HIF-1α and PD-L1, thus inhibiting the growth of subcutaneous xenograft HCC tumours." @default.
• W3213961504 created "2021-11-22" @default.
• W3213961504 creator A5000039090 @default.
• W3213961504 creator A5001260120 @default.
• W3213961504 creator A5002500632 @default.
• W3213961504 creator A5015565032 @default.
• W3213961504 creator A5025343204 @default.
• W3213961504 creator A5025732023 @default.
• W3213961504 creator A5036294961 @default.
• W3213961504 creator A5043660513 @default.
• W3213961504 creator A5043923290 @default.
• W3213961504 creator A5044267673 @default.
• W3213961504 creator A5045281956 @default.
• W3213961504 creator A5055777557 @default.
• W3213961504 creator A5069352476 @default.
• W3213961504 date "2021-11-15" @default.
• W3213961504 modified "2023-10-14" @default.
• W3213961504 title "Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma" @default.
• W3213961504 cites W1495626828 @default.
• W3213961504 cites W1557991089 @default.
• W3213961504 cites W1996398553 @default.
• W3213961504 cites W2012876493 @default.
• W3213961504 cites W2016734944 @default.
• W3213961504 cites W2016983859 @default.
• W3213961504 cites W2019648143 @default.
• W3213961504 cites W2033556029 @default.
• W3213961504 cites W2044149912 @default.
• W3213961504 cites W2064058305 @default.
• W3213961504 cites W2069372863 @default.
• W3213961504 cites W2074824347 @default.
• W3213961504 cites W2100088098 @default.
• W3213961504 cites W2131577873 @default.
• W3213961504 cites W2147157289 @default.
• W3213961504 cites W2149360266 @default.
• W3213961504 cites W2265131395 @default.
• W3213961504 cites W2270816365 @default.
• W3213961504 cites W2317624096 @default.
• W3213961504 cites W2337795947 @default.
• W3213961504 cites W2401056916 @default.
• W3213961504 cites W2514967531 @default.
• W3213961504 cites W2599604693 @default.
• W3213961504 cites W2735127852 @default.
• W3213961504 cites W2790745355 @default.
• W3213961504 cites W2807322325 @default.
• W3213961504 cites W2888408613 @default.
• W3213961504 cites W2891662274 @default.
• W3213961504 cites W2891926051 @default.
• W3213961504 cites W2897214576 @default.
• W3213961504 cites W2901513648 @default.
• W3213961504 cites W2903686952 @default.
• W3213961504 cites W2911909558 @default.
• W3213961504 cites W2951296513 @default.
• W3213961504 cites W2954863566 @default.
• W3213961504 cites W2967571151 @default.
• W3213961504 cites W2969748573 @default.
• W3213961504 cites W2979448139 @default.
• W3213961504 cites W2982756540 @default.
• W3213961504 cites W2987284967 @default.
• W3213961504 cites W2997223650 @default.
• W3213961504 cites W3003087315 @default.
• W3213961504 cites W3007400348 @default.
• W3213961504 cites W3011027479 @default.
• W3213961504 cites W3091378062 @default.
• W3213961504 cites W3115178885 @default.
• W3213961504 doi "https://doi.org/10.4251/wjgo.v13.i11.1725" @default.
• W3213961504 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8603453" @default.
• W3213961504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34853646" @default.
• W3213961504 hasPublicationYear "2021" @default.
• W3213961504 type Work @default.
• W3213961504 sameAs 3213961504 @default.
• W3213961504 citedByCount "5" @default.
• W3213961504 countsByYear W32139615042022 @default.
• W3213961504 countsByYear W32139615042023 @default.
• W3213961504 crossrefType "journal-article" @default.
• W3213961504 hasAuthorship W3213961504A5000039090 @default.
• W3213961504 hasAuthorship W3213961504A5001260120 @default.
• W3213961504 hasAuthorship W3213961504A5002500632 @default.
• W3213961504 hasAuthorship W3213961504A5015565032 @default.
• W3213961504 hasAuthorship W3213961504A5025343204 @default.
• W3213961504 hasAuthorship W3213961504A5025732023 @default.
• W3213961504 hasAuthorship W3213961504A5036294961 @default.
• W3213961504 hasAuthorship W3213961504A5043660513 @default.
• W3213961504 hasAuthorship W3213961504A5043923290 @default.
• W3213961504 hasAuthorship W3213961504A5044267673 @default.
• W3213961504 hasAuthorship W3213961504A5045281956 @default.
• W3213961504 hasAuthorship W3213961504A5055777557 @default.
• W3213961504 hasAuthorship W3213961504A5069352476 @default.
• W3213961504 hasBestOaLocation W32139615041 @default.
• W3213961504 hasConcept C104317684 @default.
• W3213961504 hasConcept C126322002 @default.
• W3213961504 hasConcept C127561419 @default.
• W3213961504 hasConcept C190283241 @default.
• W3213961504 hasConcept C203014093 @default.
• W3213961504 hasConcept C2776390293 @default.
• W3213961504 hasConcept C2776694085 @default.
• W3213961504 hasConcept C2777397205 @default.
• W3213961504 hasConcept C2778019345 @default.
• W3213961504 hasConcept C2778239845 @default.

• next